Mangalam Drugs & Organics P/E Ratio
Mangalam Drugs & Organics P/E ratio. Mangalam Drugs & Organics (MANGALAM) P/E ratio is not applicable — EPS (TTM) ₹-28.05, 3 consecutive loss quarters. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company has reported losses in the last 3 quarters. P/E ratio is not applicable during loss periods.
Consecutive Loss Quarters: 3
Current EPS: ₹-28.05
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -8.48 | -13 | Loss |
| Jun 2026 | -4.83 | -8 | Loss |
| Sept 2025 | -4.64 | -7 | Loss |
| Mar 2025 | 0.04 | 0 | Profit |
| Jun 2025 | -8.72 | -14 | Loss |
| Dec 2025 | -6.21 | -10 | Loss |
| Sept 2024 | 1.70 | 3 | Profit |
| Mar 2024 | 2.23 | 4 | Profit |
Healthcare Peers with Valid P/E Ratios — MANGALAM Comparison
Healthcare sector average P/E 55.63, median 32.33 — MANGALAM excluded (negative EPS).
Sector Average PE
55.63
Sector Median PE
32.33
Lowest PE
2.04
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.28 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.78 | ₹65 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Mangalam Drugs & Organics screener.
- Examine MANGALAM Q4 results for recent quarterly revenue, profit and EPS trends.
- Also explore MANGALAM stock price history to track price trends across different timeframes.